Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ragu Ratnakumaran

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
European Urology|April 2, 2026
Reply to Therese Kang and Wee Loon Ong's Letter to the Editor re: Ragu Ratnakumaran, Douglas H. Brand, Archana Sasitharan, et al. Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study. Eur Urol 2026;89:71-9Ragu Ratnakumaran, Alison C Tree
International Journal of Radiation Oncology, Biology, Physics|September 1, 2024
Toxicity After Prostate Radiation Therapy: Addressing the Transurethral Resection of the Prostate (TURP) ChallengeRagu Ratnakumaran, Thomas Zilli
Cancers|February 25, 2023
The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B StudyRagu Ratnakumaran, Victoria Hinder, Douglas Brand, et al.
Clinical and Translational Radiation Oncology|April 8, 2024
Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicityRagu Ratnakumaran, Jonathan Mohajer, Samuel J Withey, et al.
Cancers|June 19, 2024
Stereotactic Body Radiotherapy (SBRT) to Localised Prostate Cancer in the Era of MRI-Guided Adaptive Radiotherapy: Doses Delivered in the HERMES Trial Comparing Two- and Five-Fraction TreatmentsRosalyne Westley, Francis Casey, Adam Mitchell, et al.
European Urology|October 23, 2025
Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B StudyRagu Ratnakumaran, Douglas H Brand, Archana Sasitharan, et al.
International Journal of Radiation Oncology, Biology, Physics|January 25, 2025
Dosimetric Comparison of CyberKnife and Conventional Linac Prostate Stereotactic Body Radiation Therapy Plans: Analysis of the PACE-B StudyRagu Ratnakumaran, Archana Sasitharan, Asadullah Khan, et al.
International Journal of Radiation Oncology, Biology, Physics|September 30, 2023
Interim Toxicity Analysis From the Randomized HERMES Trial of 2- and 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation TherapyRosalyne Laura Westley, Katie Biscombe, Alex Dunlop, et al.
International Journal of Radiation Oncology, Biology, Physics|May 22, 2025
HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation TherapySian Cooper, Rosalyne L Westley, Katie Biscombe, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
European Urology|April 2, 2026
Reply to Therese Kang and Wee Loon Ong's Letter to the Editor re: Ragu Ratnakumaran, Douglas H. Brand, Archana Sasitharan, et al. Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study. Eur Urol 2026;89:71-9Ragu Ratnakumaran, Alison C Tree
International Journal of Radiation Oncology, Biology, Physics|September 1, 2024
Toxicity After Prostate Radiation Therapy: Addressing the Transurethral Resection of the Prostate (TURP) ChallengeRagu Ratnakumaran, Thomas Zilli
Cancers|February 25, 2023
The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B StudyRagu Ratnakumaran, Victoria Hinder, Douglas Brand, et al.
Clinical and Translational Radiation Oncology|April 8, 2024
Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicityRagu Ratnakumaran, Jonathan Mohajer, Samuel J Withey, et al.
Cancers|June 19, 2024
Stereotactic Body Radiotherapy (SBRT) to Localised Prostate Cancer in the Era of MRI-Guided Adaptive Radiotherapy: Doses Delivered in the HERMES Trial Comparing Two- and Five-Fraction TreatmentsRosalyne Westley, Francis Casey, Adam Mitchell, et al.
European Urology|October 23, 2025
Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B StudyRagu Ratnakumaran, Douglas H Brand, Archana Sasitharan, et al.
International Journal of Radiation Oncology, Biology, Physics|January 25, 2025
Dosimetric Comparison of CyberKnife and Conventional Linac Prostate Stereotactic Body Radiation Therapy Plans: Analysis of the PACE-B StudyRagu Ratnakumaran, Archana Sasitharan, Asadullah Khan, et al.
International Journal of Radiation Oncology, Biology, Physics|September 30, 2023
Interim Toxicity Analysis From the Randomized HERMES Trial of 2- and 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation TherapyRosalyne Laura Westley, Katie Biscombe, Alex Dunlop, et al.
International Journal of Radiation Oncology, Biology, Physics|May 22, 2025
HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation TherapySian Cooper, Rosalyne L Westley, Katie Biscombe, et al.
Pageof 1